Carboxycyclophosphamide
Carboxycyclophosphamide is a metabolite of the chemotherapy drug cyclophosphamide. Cyclophosphamide is an alkylating agent used in the treatment of various types of cancer, including lymphoma, leukemia, and some solid tumors.
Metabolism[edit]
Cyclophosphamide is a prodrug that requires metabolic activation by the liver to exert its therapeutic effects. The activation process involves the conversion of cyclophosphamide to its active metabolites, including 4-hydroxycyclophosphamide and aldophosphamide. These metabolites are further converted to phosphoramide mustard and acrolein, which are responsible for the drug's cytotoxic effects. Carboxycyclophosphamide is one of the inactive metabolites formed during this metabolic process.
Mechanism of Action[edit]
The active metabolites of cyclophosphamide, particularly phosphoramide mustard, function by forming DNA cross-links in rapidly dividing cells. This leads to apoptosis or programmed cell death, thereby inhibiting the growth of cancer cells. Carboxycyclophosphamide, being an inactive metabolite, does not contribute to the drug's cytotoxic effects.
Clinical Significance[edit]
The presence of carboxycyclophosphamide in the body is an indicator of cyclophosphamide metabolism. Monitoring the levels of carboxycyclophosphamide and other metabolites can help in understanding the pharmacokinetics of cyclophosphamide in individual patients. This can be particularly useful in optimizing dosage and minimizing side effects.
Side Effects[edit]
While carboxycyclophosphamide itself is not associated with specific side effects, the parent drug cyclophosphamide can cause a range of adverse effects. These include myelosuppression, hemorrhagic cystitis, nausea, and vomiting. The formation of acrolein, another metabolite, is specifically associated with hemorrhagic cystitis.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
